GEN Exclusives

More »

GEN News Highlights

More »
Mar 21, 2007

Microbix Wins Patent on Its Technology that Boosts Production of Flu Vaccine

  • Microbix Biosystems was issued a Canadian patent for its vaccine technology that is designed to boost global production of influenza vaccines.

    Last year, according to Microbix, an independent laboratory confirmed that the company’s vaccine technology delivers a two-fold increase in the yield of human influenza virus from eggs. The independent evaluation was conducted by Todd Hatchette, Ph.D., the director of virology and immunology at the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia.

    Annual global vaccine production capacity is currently only 350 million doses, far short of any potential pandemic requirement, notes Microbix. The company’s technology not only offers the potential to significantly increase flu vaccine production, explains William J. Gastle, chairman and CEO, but will also speed up development of vaccines in response to new flu strains—both important factors in combating possible future pandemics.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »